Mochi Health Review: What Its Membership Promises—and What the Contract Still Needs to Explain

01Start with the payment obligation, not the monthly equivalent

The annual membership block displays $199 for 12 months, an advertised equivalent of $17 per month and a claimed $39 saving. Crucially, it specifies that $199 is due today for the first 12 months. This is an upfront annual offer, not evidence that a member can pay $17 each month. Nor does a 12-month membership establish a 12-month medication supply or reveal whether any separate medication purchase has a minimum commitment.

A different promotion advertises $79 off membership and a first month free specifically on the one-month plan. That language does not offer free medication, and it should not be combined with the annual offer without confirmation that the promotions can be used together. The consulted pages do not establish the complete range of plans, the charge after the promotional month or the renewal price after the first annual period.

Before entering payment information, request the selected plan’s initial charge, billing interval, next charge date and subsequent price in writing. Keep the promotion and checkout terms together, especially if their wording differs. Our guide to billing intervals and commitments explains why an advertised monthly equivalent is not enough to identify an actual payment obligation. Here, the annual offer’s upfront collection is clear; its later financial terms are not.

02“Cancel anytime” leaves the prepaid balance unresolved

Mochi’s membership language advertises personalized treatment options, no hidden fees and cancellation at any time. These are useful statements of the offer, but they do not explain the mechanics of ending it. The consulted pages do not establish whether cancellation takes effect immediately or at the end of the paid period, how it must be submitted, or whether a notice deadline applies before another charge. No particular deadline should be assumed.

The central annual-plan question is whether cancellation stops only future renewal or also produces a refund for unused time. The public documentation reviewed here does not answer that question. A refund link appears, but its underlying policy was not part of the consulted documentation. Consequently, this review cannot establish refund eligibility, exclusions, processing periods or whether a consultation, prescription or pharmacy order changes the amount recoverable.

Ask for the operative cancellation and refund policies before paying, including what happens if a clinician does not prescribe medication. Also ask whether ending membership affects a pending prescription or continued access to the care team. Our explanation of refund boundaries helps distinguish permission to cancel from entitlement to money back. Mochi’s cancellation statement should not be treated as either a refund guarantee or proof that all payments are nonrefundable.

03Separate the platform, medical practice and pharmacy

Mochi’s corporate notice draws an important responsibility line. Professional medical services are provided by licensed physicians and other clinicians affiliated with independently owned and operated professional practices. Mochi Health Corp. supplies administrative and technology services to the practices it supports and says it does not itself provide professional medical services. That structure matters when determining who handles medical records, clinical decisions, billing disputes and complaints about an individual consultation.

The homepage also says members purchase medication through a network of pharmacies. The consulted material does not identify the particular practice that would treat a given member or the pharmacy that would dispense or compound a particular prescription. Those identities should be confirmed for the actual enrollment, rather than inferred from the Mochi brand. A statement that a prescription will be fulfilled does not establish which organization prepared it.

A useful enrollment record would name the treating practice, prescribing clinician, dispensing pharmacy and party collecting each payment. It should also explain where billing questions and treatment questions go. Our guide to platform, clinician and pharmacy responsibilities provides a framework for that distinction. This is especially relevant if a payment dispute involves membership fees while a separate concern involves a prescription, product quality or a pharmacy order already underway.

04Enrollment buys access to evaluation, not a promised prescription

The advertised process begins with a short health-history questionnaire. The tirzepatide page then describes a live, 30-minute video visit with a doctor. That figure is the appointment’s stated duration, not a promise that an appointment will be available within 30 minutes. The homepage says laboratory testing may be ordered if needed to evaluate health. It does not establish the cost of those tests or how quickly evaluation will be completed.

Mochi invites members to choose a provider it describes as board certified and a registered dietitian. This review did not independently verify individual credentials. The medication pages explicitly leave prescribing to the provider’s discretion, and the injectable compounded-product pages require a written prescription from a licensed provider. Enrollment therefore should not be interpreted as a guarantee of receiving a particular medication, formulation or prescription at all.

The consulted pages do not establish complete eligibility criteria, including minimum age, BMI requirements or contraindications. They also do not explain what happens to membership payments if evaluation ends without a prescription. Those are separate questions worth resolving before checkout: whether the service can evaluate someone in their state, whether the desired treatment is available there, and what financial obligation remains if the clinician recommends a different approach or no medication.

05Medication prices are separate—and the formulation matters

Mochi advertises compounded once-weekly subcutaneous tirzepatide starting at $90 plus membership, and compounded once-weekly subcutaneous semaglutide starting at $60 plus membership. Both pages state that price varies with the prescribed dose. Neither cited price block identifies its supply period. It would therefore be misleading to describe those figures as monthly totals, add them to a monthly membership equivalent, or assume they purchase a particular quantity.

The oral semaglutide page is more explicit about timing: it advertises a compounded, once-weekly oral pill starting at $62 per month plus membership, subject to prescribing discretion. That is the provider’s product description, not dosing guidance or evidence that it is interchangeable with another semaglutide formulation. The homepage also lists compounded oral orforglipron. The consulted material does not establish a final price for that offering.

The broader catalog includes Zepbound, injectable Wegovy, Mounjaro, Ozempic, Foundayo, a product labeled Wegovy Pill and metformin. Mochi describes Mounjaro, Ozempic and metformin in diabetes-related terms; a catalog listing alone does not guarantee access for a particular use. It also makes product-specific approval claims, including for Wegovy Pill, that this review does not independently verify. Request a written treatment quote naming the exact product, formulation, route, quantity, supply period and separate membership charge.

06Membership, insurance and diagnostics are different billing layers

The membership subscription expressly excludes medications and diagnostic services. That exclusion is more informative than the broad promise of no hidden fees: even a fully disclosed membership charge is not the complete cost of treatment. If labs are ordered, the consulted pages do not establish their price, who bills for them or whether insurance will cover them. Likewise, the medication starting prices do not resolve the total for a particular prescription.

Mochi’s insurance-care block says visits are billed through insurance and that the copay is shown before a person commits. Elsewhere, it advertises unlimited care-team visits included in membership. These statements should be read together, not collapsed into a promise that every visit is free. The reviewed material does not fully explain how each insurance and self-pay pathway interacts with membership, or which charges apply under every available plan.

If medication is prescribed, Mochi says it handles prior authorization and coordinates delivery or local pickup; it also advertises cash-pay and compounded options for people without insurance. Prior-authorization help is a service, not a guarantee of approval or medication coverage. NIDDK notes that insurance coverage for weight-management medicines varies by plan. Confirm consultation benefits and prescription benefits separately, including the amount owed if coverage is denied or the prescribed product changes.

07Ongoing care is described more clearly than delivery deadlines

Mochi advertises unlimited visits with the care team as part of membership. The homepage describes video visits as often as needed, nutrition and wellness guidance, and follow-up laboratory testing. This establishes a broader offering than prescription fulfillment alone. It does not, however, settle whether every requested appointment can occur promptly, whether a particular clinician remains available, or how separately billed diagnostic work fits into the continuing-care plan.

The company also advertises 24/7 care-team support, including insurance and prior-authorization assistance. No response-time commitment is established in the consulted text. The medication pages promise fulfillment and delivery to the door, while the homepage mentions delivery or local pickup and describes pharmacy-network shipping as reliable. None of those statements provides a documented dispatch deadline, transit period or arrival guarantee. The reviewed pages also do not confirm Spanish-language care or interpretation.

Before an order is placed, ask who provides tracking, handles an address correction and decides on replacement after a delivery problem. The consulted documentation does not establish cold-chain or replacement terms. FDA advises patients not to use an injectable GLP-1 drug that arrives warm or with insufficient refrigeration and to contact the provider or dispensing pharmacy. That safety instruction is distinct from whether the seller will replace the shipment or refund its cost.

08Product disclosures and testimonials do not establish outcomes

Mochi discloses that compounded medications are not FDA approved or evaluated by the agency for safety, effectiveness or quality. FDA likewise explains that compounded preparations do not undergo its premarket review. Approval applies to a particular product, not to Mochi as a platform or to a compounded preparation because it shares an ingredient name. Nonapproval alone also does not demonstrate clinical inequivalence or establish the quality of a particular pharmacy’s product.

FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. That recommendation makes the actual product and dispensing channel important questions for the treating clinician. It should not be turned into a categorical legal conclusion about Mochi. The consulted pages do not identify the pharmacy for an individual order or establish its specific preparation details.

Mochi also discloses that members appearing in its testimonials were compensated for sharing their experiences. Those accounts are advertising material, not independent evidence of typical outcomes. This review found documentation of offered services, rather than provider-specific clinical results. Clearer billing or cancellation terms would improve the enrollment decision, but would not prove effectiveness. Clinical decisions still require discussion of health conditions, other medicines, potential side effects and costs with the treating clinician.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. Mochi Health — medications/compounded semaglutide ↗
4. Mochi Health — medications/compounded tirzepatide ↗
5. Mochi Health — official website ↗
6. Mochi Health — medications/compounded semaglutide pill ↗

Continue reading

• A Monthly Price Is Not Always a Monthly Commitment
• GLP-1 Refund Guarantees: What Is Covered, What Is Excluded, and When Money Returns
• Platform, Clinician, Pharmacy: Who Is Responsible for Your GLP-1 Care?
• What to Ask for in a Written GLP-1 Quote Before You Enroll